Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Phase 1 Completed 33 enrolled AstraZeneca Fortrea Clinical Research Unit Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.

Timeline

Start: 2024-12-19
Primary completion: 2025-10-02
Completion: 2025-10-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD5004	Unknown	—	Oral

Indications

No indication recorded.